超声与CT引导下射频消融治疗肝脏肿瘤的疗效分析

US and CT Guided Radiofrequency Ablation for the Treatment of Hepatic Tumors:Analysis of Therapeutic Effect

目的比较超声引导与CT引导下射频消融(RFA)治疗肝脏恶性肿瘤的疗效。方法回顾性分析2009年7月至2012年9月在本院行RFA治疗的病例资料。B超组42例(共47个病灶),CT组19例(共23个病灶),比较两组病例病灶中位无活性时间及不同时期的复发率。结果 B超引导下RFA后病灶中位无活性时间为7个月,CT引导下RFA后病灶无活性时间为8个月,6个月时累积复发率分别为42.9%和31.4%,但均未显示统计学差异。随访期内2组消融病灶的局部控制率相差不明显。结论超声引导与CT引导下RFA治疗肝脏恶性肿瘤的疗效相似。

Objective To compare the efficacy of US-guided radiofrequency ablation with the efficacy of CT-guided radiofrequency ablation in treating hepatic malignancies. Methods During the period from July 2009 to September 2012 at authors＇ hospital, a total of 61 patients with hepatic malignancy received radiofrequency ablation （RFA）. The clinical data were retrospective analyzed. Forty-two patients （47 lesions in total） received US-guided radiofrequency ablation （US group）, while 19 patients （23 lesions in total） underwent CT-guided radiofrequency ablation. The median disease-free survival time and the recurrence rate at different stage were determined, and the results were compared between the two groups. Results The median disease-free survival time of US group and CT group was 7 months and 8 months respectively. The 6-month cumulated recurrence rate in US group and CT group was 31.4% and 42.9% respectively. The differences between the two groups were not statistically significant. During the follow-up period, the difference in the control rate of the ablated lesion between the two groups was not significant. Conclusion For the treatment of hepatic malignancies, US-guided radiofrequency ablation and CT-guided radiofrequency ablation has the similar therapeutic effect.